<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id>
        <journal-id journal-id-type="iso-abbrev">Int J Infect Dis</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3815</journal-id>
        <journal-id journal-id-type="pmc-domain">pheelsevier</journal-id>
        <journal-title-group>
          <journal-title>International Journal of Infectious Diseases</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1201-9712</issn>
        <issn pub-type="epub">1878-3511</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Elsevier - PMC COVID-19 Collection</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8531242</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8531242.1</article-id>
        <article-id pub-id-type="pmcaid">8531242</article-id>
        <article-id pub-id-type="pmcaiid">8531242</article-id>
        <article-id pub-id-type="pmid">34688944</article-id>
        <article-id pub-id-type="doi">10.1016/j.ijid.2021.10.030</article-id>
        <article-id pub-id-type="pii">S1201-9712(21)00818-3</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" id="au0001">
            <name name-style="western">
              <surname>Asano</surname>
              <given-names initials="M">Michiko</given-names>
            </name>
            <xref rid="aff0001" ref-type="aff">a</xref>
            <xref rid="cor0001" ref-type="corresp">⁎</xref>
          </contrib>
          <contrib contrib-type="author" id="au0002">
            <name name-style="western">
              <surname>Okada</surname>
              <given-names initials="H">Hiroshi</given-names>
            </name>
            <xref rid="aff0002" ref-type="aff">b</xref>
          </contrib>
          <contrib contrib-type="author" id="au0003">
            <name name-style="western">
              <surname>Itoh</surname>
              <given-names initials="Y">Yohji</given-names>
            </name>
            <xref rid="aff0003" ref-type="aff">c</xref>
          </contrib>
          <contrib contrib-type="author" id="au0004">
            <name name-style="western">
              <surname>Hirata</surname>
              <given-names initials="H">Hajime</given-names>
            </name>
            <xref rid="aff0004" ref-type="aff">d</xref>
          </contrib>
          <contrib contrib-type="author" id="au0005">
            <name name-style="western">
              <surname>Ishikawa</surname>
              <given-names initials="K">Kensuke</given-names>
            </name>
            <xref rid="aff0005" ref-type="aff">e</xref>
          </contrib>
          <contrib contrib-type="author" id="au0006">
            <name name-style="western">
              <surname>Yoshida</surname>
              <given-names initials="E">Erika</given-names>
            </name>
            <xref rid="aff0006" ref-type="aff">f</xref>
          </contrib>
          <contrib contrib-type="author" id="au0007">
            <name name-style="western">
              <surname>Matsui</surname>
              <given-names initials="A">Akiko</given-names>
            </name>
            <xref rid="aff0005" ref-type="aff">e</xref>
          </contrib>
          <contrib contrib-type="author" id="au0008">
            <name name-style="western">
              <surname>Kelly</surname>
              <given-names initials="EJ">Elizabeth J.</given-names>
            </name>
            <xref rid="aff0007" ref-type="aff">g</xref>
          </contrib>
          <contrib contrib-type="author" id="au0009">
            <name name-style="western">
              <surname>Shoemaker</surname>
              <given-names initials="K">Kathryn</given-names>
            </name>
            <xref rid="aff0008" ref-type="aff">h</xref>
          </contrib>
          <contrib contrib-type="author" id="au0010">
            <name name-style="western">
              <surname>Olsson</surname>
              <given-names initials="U">Urban</given-names>
            </name>
            <xref rid="aff0009" ref-type="aff">i</xref>
          </contrib>
          <contrib contrib-type="author" id="au0011">
            <name name-style="western">
              <surname>Vekemans</surname>
              <given-names initials="J">Johan</given-names>
            </name>
            <xref rid="aff0009" ref-type="aff">i</xref>
          </contrib>
          <aff id="aff0001">
            <label>a</label>Medical Science, BioPharmaceuticals, R&amp;D, AstraZeneca, Tokyo, Japan</aff>
          <aff id="aff0002">
            <label>b</label>Medical Science, BioPharmaceuticals, R&amp;D, AstraZeneca, Osaka, Japan</aff>
          <aff id="aff0003">
            <label>c</label>Science and Data Analytics, Oncology R&amp;D, AstraZeneca, Osaka, Japan</aff>
          <aff id="aff0004">
            <label>d</label>Clinical Science, BioPharmaceuticals, R&amp;D, AstraZeneca, Osaka, Japan</aff>
          <aff id="aff0005">
            <label>e</label>Science and Data Analytics, R&amp;D, AstraZeneca, Osaka, Japan</aff>
          <aff id="aff0006">
            <label>f</label>Biopharma Clinical Operations, Development Operations, BioPharmaceuticals R&amp;D, AstraZeneca, Tokyo, Japan</aff>
          <aff id="aff0007">
            <label>g</label>Microbial Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff>
          <aff id="aff0008">
            <label>h</label>Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff>
          <aff id="aff0009">
            <label>i</label>Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor0001">
            <label>⁎</label>Corresponding author. Address: 3 Chome-1-1 Shibaura, Minato City, Medical Science, BioPharmaceuticals, R&amp;D, AstraZeneca, Tokyo 108-0023, Japan.</corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <month>1</month>
          <year>2022</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>22</day>
          <month>10</month>
          <year>2021</year>
        </pub-date>
        <volume>114</volume>
        <issue-id pub-id-type="pmc-issue-id">392302</issue-id>
        <fpage>165</fpage>
        <lpage>174</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="main.pdf" />
        <abstract id="abs0002">
          <sec>
            <title>Background</title>
            <p>Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multi-centre trial (<ext-link ext-link-type="pmc:clinical-trial" ns0:href="NCT04568031">NCT04568031</ext-link>).</p>
          </sec>
          <sec>
            <title>Methods</title>
            <p>Adults (<italic toggle="yes">n</italic>=256, age ≥18 years) seronegative for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were stratified by age into 18–55- (<italic toggle="yes">n</italic>=128), 56–69- (<italic toggle="yes">n</italic>=86) and ≥70-year-old cohorts (<italic toggle="yes">n</italic>=42), and randomized 3:1 to receive AZD1222 or placebo (two intramuscular injections 4 weeks apart). Immunogenicity and safety were coprimary endpoints. Data collected up to Day 57 are reported.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p>Positive seroresponses to SARS-CoV-2 spike and receptor-binding domain antigens were seen in all 174 participants who received two doses of AZD1222. Neutralizing antibody seroresponses were seen in 67.5%, 60.3% and 50.0% of participants receiving AZD1222 aged 18–55, 56–69 and ≥70 years, respectively. Solicited adverse events (AEs) were typically mild/moderate in severity and included pain and tenderness at the injection site, malaise, fatigue, muscle pain and headache. Common unsolicited AEs included pain and tenderness at the injection site, fatigue and elevated body temperature. No vaccine-related serious AEs or deaths were reported.</p>
          </sec>
          <sec>
            <title>Conclusions</title>
            <p>AZD1222 elicited a strong humoral immune response against SARS-CoV-2, and was well tolerated in Japanese participants, including elderly participants.</p>
          </sec>
        </abstract>
        <kwd-group id="keys0001">
          <title>Keywords</title>
          <kwd>COVID-19</kwd>
          <kwd>ChAdOx1 nCoV-19</kwd>
          <kwd>AZD1222</kwd>
          <kwd>Japan</kwd>
          <kwd>Elderly adult</kwd>
          <kwd>Humoral response</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="sec0001">
        <title>Introduction</title>
        <p id="para0009">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has resulted in widespread morbidity and mortality, prompting the most extensive and rapid global vaccine development programme in history (<xref rid="bib0033" ref-type="bibr">World Health Organization, 2020a</xref>). Accelerated development and approval has been crucial to providing effective, well-tolerated vaccines against symptomatic SARS-CoV-2 infection (COVID-19). By the end of 2020, several vaccines had reached their phase 3 efficacy milestones and received emergency authorization for use (<xref rid="bib0023" ref-type="bibr">Polack et al., 2020</xref>; <xref rid="bib0003" ref-type="bibr">Baden et al., 2021</xref>; <xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>, <xref rid="bib0030" ref-type="bibr">Voysey et al., 2021b</xref>).</p>
        <p id="para0010">As of 21 September 2021, 1,679,116 confirmed cases of COVID-19 and 17,233 deaths related to the disease have been reported in Japan, with greater numbers seen in older age groups (<xref rid="bib0034" ref-type="bibr">World Health Organization, 2020b</xref>; <xref rid="bib0020" ref-type="bibr">National Institute of Population and Social Security Research, 2021</xref>). In 2019, people aged ≥65 years accounted for 28.4% of the Japanese population (<xref rid="bib0026" ref-type="bibr">Statistics Bureau of Japan, 2021</xref>). Age is a prominent risk factor for COVID-19 morbidity and mortality, with adults aged ≥70 years at greater risk of severe disease and death than younger age groups (<xref rid="bib0035" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="bib0005" ref-type="bibr">Chen et al., 2021</xref>). Risk of severe disease is also increased by the presence of comorbidities, including hypertension, cardiovascular disease, diabetes and obesity (<xref rid="bib0035" ref-type="bibr">Wu et al., 2020</xref>). The rapid approval of COVID-19 vaccines in Japan is therefore crucial to help protect an aging population.</p>
        <p id="para0011">The AZD1222 (ChAdOx1 nCoV-19) vaccine is a replication-deficient simian adenovirus-vectored vaccine encoding the full-length SARS-CoV-2 spike protein (<xref rid="bib0012" ref-type="bibr">Folegatti et al., 2020</xref>). The immunogenicity, safety and efficacy of AZD1222 is being assessed globally in randomized controlled trials (<xref rid="bib0012" ref-type="bibr">Folegatti et al., 2020</xref>; <xref rid="bib0002" ref-type="bibr">AstraZeneca, 2021</xref>; <xref rid="bib0004" ref-type="bibr">Barrett et al., 2021</xref>; <xref rid="bib0010" ref-type="bibr">Ewer et al., 2021</xref>; <xref rid="bib0024" ref-type="bibr">Ramasamy et al., 2021</xref>; <xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>, <xref rid="bib0030" ref-type="bibr">Voysey et al., 2021b</xref>). In a pooled analysis of four trials conducted in the UK (phase 1/2 and 2/3), Brazil (phase 3) and South Africa (phase 1/2), AZD1222 exhibited an acceptable safety profile and overall vaccine efficacy of 66.7% [95% confidence interval (CI) 57.4–74.0] against COVID-19 &gt;14 days after the second dose (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>). A single dose of AZD1222 induced spike and receptor-binding domain (RBD) antibodies as well as neutralizing antibody (nAb) titres against SARS-CoV-2, which were increased substantially after a second dose 28 days later (<xref rid="bib0012" ref-type="bibr">Folegatti et al., 2020</xref>; <xref rid="bib0004" ref-type="bibr">Barrett et al., 2021</xref>; <xref rid="bib0010" ref-type="bibr">Ewer et al., 2021</xref>; <xref rid="bib0024" ref-type="bibr">Ramasamy et al., 2021</xref>).</p>
        <p id="para0012">A growing number of studies suggest that seroresponse and presence of nAbs may indicate protection against COVID-19 (<xref rid="bib0001" ref-type="bibr">Addetia et al., 2020</xref>; <xref rid="bib0012" ref-type="bibr">Folegatti et al., 2020</xref>; <xref rid="bib0025" ref-type="bibr">Robbiani et al., 2020</xref>; <xref rid="bib0031" ref-type="bibr">Wang et al., 2020</xref>; <xref rid="bib0013" ref-type="bibr">Hall et al., 2021</xref>; <xref rid="bib0014" ref-type="bibr">Hansen et al., 2021</xref>; <xref rid="bib0015" ref-type="bibr">Harvey et al., 2021</xref>; <xref rid="bib0016" ref-type="bibr">Krammer, 2021</xref>; <xref rid="bib0022" ref-type="bibr">Pilz et al., 2021</xref>). For the development of a vaccine, the presence of an immune response can provide a reasonable indication of efficacy, and immunogenic assessments can be made in a shorter time and with smaller sample sizes compared with efficacy assessments.</p>
        <p id="para0013">This article reports immunogenicity and safety results from a randomized, placebo-controlled, phase 1/2 trial of AZD1222 in Japanese adults. To the authors’ knowledge, this is the first randomized, double-blind, placebo-controlled study to evaluate immunogenicity and safety of a replication-deficient simian adenovirus-vectored vaccine in an East Asian country.</p>
      </sec>
      <sec id="sec0002">
        <title>Methods</title>
        <sec id="sec0003">
          <title>Study design and participants</title>
          <p id="para0014">This phase 1/2, randomized, double-blind, parallel-group, placebo-controlled trial (ClinicalTrials.gov identifier: <ext-link ext-link-type="pmc:clinical-trial" ns0:href="NCT04568031">NCT04568031</ext-link>) is being conducted at five centres in Japan, with a planned study duration of 1 year following dosing for each participant. Safety and immunogenicity data up to Day 57 for all enrolled participants are reported here.</p>
        </sec>
        <sec id="sec0004">
          <title>Ethics and oversight</title>
          <p id="para0015">The study is being conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The protocol, including amendments and consent form, were approved by an institutional review board prior to study initiation. All participants provided written informed consent before enrolment.</p>
        </sec>
        <sec id="sec0005">
          <title>Participants</title>
          <sec id="sec0006">
            <title>Eligibility criteria</title>
            <p id="para0016">Adults aged ≥18 years, seronegative for SARS-CoV-2 at screening, and with a negative reverse-transcriptase polymerase chain reaction test for SARS-CoV-2 were eligible for inclusion. Participants with a history of laboratory-confirmed SARS-CoV-2 infection, pregnant women, new onset of fever, any confirmed or suspected immunodeficient state, receipt of any vaccine within 30 days before or after each study dose, or prior or planned receipt of an investigational or licensed vaccine or product that may impact interpretation of trial data (e.g. adenovirus-vectored vaccines or coronavirus vaccines) were excluded. Participants with severe and/or uncontrolled cardiovascular, respiratory, gastrointestinal, hepatic or renal disease, endocrine disorder or neurologic illness were also excluded. Mild/moderate, well-controlled comorbidities were allowed.</p>
          </sec>
          <sec id="sec0007">
            <title>Randomization and masking</title>
            <p id="para0017">Participants were stratified into two age cohorts: 18–55 years and ≥56 years. The ≥56-year-old cohort was further divided into subcohorts aged 56–69 years and ≥70 years. Approximately 30% of participants in the ≥56-year-old cohort were aged ≥70 years. Participants in each cohort were randomized (3:1) to receive either AZD1222 or placebo (saline) using a centralized Interactive Response Technology system.</p>
            <p id="para0018">AZD1222 and placebo were prepared by an unblinded pharmacist, in accordance with local and institutional regulations at each site. Participants, clinical investigators and sponsor staff were blinded to the study vaccination received until completion of safety data lock at Day 57.</p>
          </sec>
        </sec>
        <sec id="sec0008">
          <title>Study procedures</title>
          <sec id="sec0009">
            <title>Vaccination</title>
            <p id="para0019">AZD1222 was manufactured in accordance with current Good Manufacturing Practice guidelines (AstraZeneca K.K., Osaka, Japan; MedImmune Pharma BV, Nijmegen, The Netherlands). Participants received two doses of AZD1222 (5 × 10<sup>10</sup> viral particles/dose) or placebo (saline; 0.9% weight/volume) on Days 1 and 29, administered as intramuscular injections into the deltoid muscle.</p>
          </sec>
          <sec id="sec0010">
            <title>Clinical and immunogenicity assessments</title>
            <p id="para0020">Blood samples for immunogenicity assessments were collected before and after each dose (serology: Days 1, 15, 29, 43 and 57; nAb: Days 1, 29 and 57). Humoral responses at baseline and after dosing were assessed using a validated, multiplex, electrochemiluminescent immunoassay against the SARS-CoV-2 spike, RBD and nucleocapsid antigens (PPD Vaccines, Richmond, VA, USA), and a validated HIV-1-based pseudo-virus neutralization assay (Monogram Biosciences, South San Francisco, CA, USA).</p>
          </sec>
          <sec id="sec0011">
            <title>Safety assessments</title>
            <p id="para0021">Participants were monitored for 30 min after dosing to assess for adverse events (AEs). Solicited AEs were predefined as local (pain and tenderness at the injection site, redness, swelling and induration) or systemic (fever, chills, muscle pain, fatigue, headache, malaise, nausea and vomiting) and were collected by participants using an electronic diary for 6 days after each dose (Days 1–7 and Days 29–35). Unsolicited AEs were recorded for 28 days following each dose (Days 1–29 and Days 29–57).</p>
            <p id="para0022">Blood samples were collected at Days 1, 8, 29, 36 and 57 for determination of clinical laboratory safety, including assessment of haemoglobin concentration, leukocyte count, platelet count and clinical chemistry.</p>
            <p id="para0023">Severity of safety endpoints was assessed according to toxicity grading scales adapted from Food and Drug Administration (FDA) grading guidance.</p>
          </sec>
        </sec>
        <sec id="sec0012">
          <title>Outcomes</title>
          <p id="para0024">The coprimary endpoints were immunogenicity, measured by anti-SARS-CoV-2 spike seroresponse (≥4-fold rise in titre from Day 1 baseline value) (<xref rid="bib0007" ref-type="bibr">European Medicines Agency, 2018</xref>) at Day 57 following vaccination with AZD1222, and safety, measured by occurrence of solicited local and systemic reactogenicity signs/symptoms in the 6 days after each dose; occurrence of unsolicited AEs, serious AEs (SAEs) and AEs of special interest (AESIs) for 28 days after each dose; and change from baseline in safety laboratory measures.</p>
          <p id="para0025">Secondary endpoints included proportion of participants with a seroresponse for the RBD antigen and SARS-CoV-2 nAb 28 days after the second dose of AZD1222 (Day 57); geometric mean titre (GMT) and geometric mean fold rise of immunogenicity against SARS-CoV-2 spike and RBD antigens and SARS-CoV-2 nAb at each time point up to Day 365; and occurrence of SAEs and AESIs up to Day 365.</p>
        </sec>
        <sec id="sec0013">
          <title>Statistical analyses</title>
          <sec id="sec0014">
            <title>Sample size calculations</title>
            <p id="para0026">A sample size of 128 participants (96 and 32 randomized to AZD1222 and placebo, respectively) in each cohort was determined mainly for the evaluation of safety and based on feasibility. With a sample size of 96 participants in the AZD1222 arm for each cohort, at least one participant with an AE at an incidence of 2.5% could be detected with a probability of approximately 90%.</p>
          </sec>
          <sec id="sec0015">
            <title>Analysis of study endpoints</title>
            <p id="para0027">The proportions of participants with a seroresponse for the SARS-CoV-2 spike and RBD antigens, as well as for nAb, were compared between AZD1222 and placebo using Fisher's exact test at the two-sided 5% alpha level for each cohort. Two-sided 95% CIs were calculated using the Clopper–Pearson method for proportions within each cohort/subcohort. Given the exploratory nature of the study, no adjustment for multiple comparisons and multiplicity was performed; only nominal <italic toggle="yes">P</italic>-values were provided for immunogenicity endpoints. All statistical analyses were conducted using SAS Version 9.4.</p>
            <p id="para0028">Assessments of immunogenicity were performed on the fully vaccinated analysis set (FVS), which included all participants who received two study doses, had no protocol deviations judged to potentially interfere with generation/interpretation of immune responses, and did not exhibit a seroresponse (≥4-fold rise in titre from the Day 1 baseline value) to nucleocapsid antibodies by Meso Scale Discovery serology assay up to Day 57. Safety analyses (unless otherwise stated) were performed on the total vaccinated analysis set (TVS), which included all participants who received at least one dose of study intervention. Data are summarized by descriptive statistics.</p>
          </sec>
        </sec>
      </sec>
      <sec id="sec0016">
        <title>Results</title>
        <sec id="sec0017">
          <title>Participant disposition</title>
          <p id="para0029">Participants were recruited from August 2020 (final data lock: 24 February 2021), with follow-up scheduled for approximately 1 year after the first dose. This study was temporarily interrupted by the safety data review on the occurrence of SAEs outside Japan. Participant disposition is outlined in <xref rid="fig0001" ref-type="fig">Figure 1</xref>
. All screen failures that were categorized as ‘Sponsor decision’ were associated with this interruption and a consequent pause in enrolment (<xref rid="fig0001" ref-type="fig">Figure 1</xref>).<fig id="fig0001" position="float" orientation="portrait">
              <label>Figure 1</label>
              <caption>
                <p>Participant disposition (CONSORT). <sup>a</sup>Including all participants who received at least one dose of study intervention. <sup>b</sup>Had seroresponse (≥4-fold rise in titre from Day 1 baseline value) to nucleocapsid antibodies by Meso Scale Discovery serology assay up to Day 57. <sup>c</sup>Had protocol deviations judged to have potential to interfere with the generation or interpretation of an immune response. The study was interrupted temporarily following the occurrence of serious adverse events in clinical trials outside Japan. All screen failures categorized as ‘Sponsor decision’ were associated with this interruption and a consequent pause in enrolment.</p>
              </caption>
              <alt-text id="alt0002">Figure 1</alt-text>
              <graphic position="float" orientation="portrait" ns0:href="gr1_lrg.jpg" />
            </fig>
          </p>
        </sec>
        <sec id="sec0018">
          <title>Participant baseline characteristics</title>
          <p id="para0030">Demographic and other participant baseline characteristics were well balanced between AZD1222 and placebo in the TVS (<xref rid="tbl0001" ref-type="table">Table 1</xref>
). At baseline, the prevalence of comorbidities associated with higher risk of severe COVID-19 was 27.0%, 4.3%, 1.6%, 1.6% and 0.4% for hypertension, obesity (body mass index ≥30 kg/m<sup>2</sup>), cardiac disorder, type 2 diabetes and type 1 diabetes, respectively. All participants were Japanese (Asian), and 32.8% (42/128) of participants aged ≥56 years were aged ≥70 years.<table-wrap position="float" id="tbl0001" orientation="portrait">
              <label>Table 1</label>
              <caption>
                <p>Participant baseline characteristics by age group.</p>
              </caption>
              <alt-text id="alt0001">Table 1</alt-text>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th valign="top" colspan="1" rowspan="1" />
                    <th colspan="2" align="center" valign="top" rowspan="1">Age 18–55 years<hr />
                    </th>
                    <th colspan="2" align="center" valign="top" rowspan="1">Age 56–69 years<hr />
                    </th>
                    <th colspan="2" align="center" valign="top" rowspan="1">Age ≥70 years<hr />
                    </th>
                    <th colspan="2" align="center" valign="top" rowspan="1">Total<hr />
                    </th>
                  </tr>
                  <tr>
                    <th valign="top" colspan="1" rowspan="1">Characteristic</th>
                    <th valign="top" colspan="1" rowspan="1">AZD1222 (<italic toggle="yes">n</italic>=96)</th>
                    <th valign="top" colspan="1" rowspan="1">Placebo (<italic toggle="yes">n</italic>=32)</th>
                    <th valign="top" colspan="1" rowspan="1">AZD1222 (<italic toggle="yes">n</italic>=65)</th>
                    <th valign="top" colspan="1" rowspan="1">Placebo (<italic toggle="yes">n</italic>=21)</th>
                    <th valign="top" colspan="1" rowspan="1">AZD1222 (<italic toggle="yes">n</italic>=31)</th>
                    <th valign="top" colspan="1" rowspan="1">Placebo (<italic toggle="yes">n</italic>=11)</th>
                    <th valign="top" colspan="1" rowspan="1">AZD1222 (<italic toggle="yes">n</italic>=192)</th>
                    <th valign="top" colspan="1" rowspan="1">Placebo (<italic toggle="yes">n</italic>=64)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Age, years</td>
                    <td valign="top" colspan="1" rowspan="1">45.6 (8.2)</td>
                    <td valign="top" colspan="1" rowspan="1">46.1 (6.7)</td>
                    <td valign="top" colspan="1" rowspan="1">61.0 (3.7)</td>
                    <td valign="top" colspan="1" rowspan="1">62.2 (3.6)</td>
                    <td valign="top" colspan="1" rowspan="1">73.1 (3.0)</td>
                    <td valign="top" colspan="1" rowspan="1">73.5 (4.7)</td>
                    <td valign="top" colspan="1" rowspan="1">55.3 (12.2)</td>
                    <td valign="top" colspan="1" rowspan="1">56.1 (12.1)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Females, <italic toggle="yes">n</italic> (%)</td>
                    <td valign="top" colspan="1" rowspan="1">25 (26.0)</td>
                    <td valign="top" colspan="1" rowspan="1">8 (25.0)</td>
                    <td valign="top" colspan="1" rowspan="1">27 (41.5)</td>
                    <td valign="top" colspan="1" rowspan="1">9 (42.9)</td>
                    <td valign="top" colspan="1" rowspan="1">13 (41.9)</td>
                    <td valign="top" colspan="1" rowspan="1">5 (45.5)</td>
                    <td valign="top" colspan="1" rowspan="1">65 (33.9)</td>
                    <td valign="top" colspan="1" rowspan="1">22 (34.4)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Weight, kg</td>
                    <td valign="top" colspan="1" rowspan="1">67.3 (14.1)</td>
                    <td valign="top" colspan="1" rowspan="1">69.4 (10.2)</td>
                    <td valign="top" colspan="1" rowspan="1">63.4 (12.3)</td>
                    <td valign="top" colspan="1" rowspan="1">60.2 (10.2)</td>
                    <td valign="top" colspan="1" rowspan="1">58.6 (9.6)</td>
                    <td valign="top" colspan="1" rowspan="1">61.7 (16.6)</td>
                    <td valign="top" colspan="1" rowspan="1">64.6 (13.2)</td>
                    <td valign="top" colspan="1" rowspan="1">65.1 (12.1)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Height, cm</td>
                    <td valign="top" colspan="1" rowspan="1">168.6 (7.3)</td>
                    <td valign="top" colspan="1" rowspan="1">169.1 (5.5)</td>
                    <td valign="top" colspan="1" rowspan="1">163.8 (8.5)</td>
                    <td valign="top" colspan="1" rowspan="1">162.9 (9.3)</td>
                    <td valign="top" colspan="1" rowspan="1">159.5 (7.2)</td>
                    <td valign="top" colspan="1" rowspan="1">161.6 (9.9)</td>
                    <td valign="top" colspan="1" rowspan="1">165.5 (8.4)</td>
                    <td valign="top" colspan="1" rowspan="1">165.8 (8.3)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup>
                    </td>
                    <td valign="top" colspan="1" rowspan="1">23.6 (4.2)</td>
                    <td valign="top" colspan="1" rowspan="1">24.2 (3.2)</td>
                    <td valign="top" colspan="1" rowspan="1">23.5 (3.4)</td>
                    <td valign="top" colspan="1" rowspan="1">22.6 (2.8)</td>
                    <td valign="top" colspan="1" rowspan="1">22.9 (2.7)</td>
                    <td valign="top" colspan="1" rowspan="1">23.4 (4.4)</td>
                    <td valign="top" colspan="1" rowspan="1">23.4 (3.7)</td>
                    <td valign="top" colspan="1" rowspan="1">23.6 (3.3)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">BMI group</td>
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">&lt;30 kg/m<sup>2</sup>, <italic toggle="yes">n</italic> (%)</td>
                    <td valign="top" colspan="1" rowspan="1">90 (93.8)</td>
                    <td valign="top" colspan="1" rowspan="1">30 (93.8)</td>
                    <td valign="top" colspan="1" rowspan="1">63 (96.9)</td>
                    <td valign="top" colspan="1" rowspan="1">21 (100.0)</td>
                    <td valign="top" colspan="1" rowspan="1">31 (100.0)</td>
                    <td valign="top" colspan="1" rowspan="1">10 (90.9)</td>
                    <td valign="top" colspan="1" rowspan="1">184 (95.8)</td>
                    <td valign="top" colspan="1" rowspan="1">61 (95.3)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">≥30 kg/m<sup>2</sup>, <italic toggle="yes">n</italic> (%)</td>
                    <td valign="top" colspan="1" rowspan="1">6 (6.3)</td>
                    <td valign="top" colspan="1" rowspan="1">2 (6.3)</td>
                    <td valign="top" colspan="1" rowspan="1">2 (3.1)</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">1 (9.1)</td>
                    <td valign="top" colspan="1" rowspan="1">8 (4.2)</td>
                    <td valign="top" colspan="1" rowspan="1">3 (4.7)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Comorbidities</td>
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                    <td valign="top" colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Hypertension</td>
                    <td valign="top" colspan="1" rowspan="1">17 (17.7)</td>
                    <td valign="top" colspan="1" rowspan="1">6 (18.8)</td>
                    <td valign="top" colspan="1" rowspan="1">19 (29.2)</td>
                    <td valign="top" colspan="1" rowspan="1">8 (38.1)</td>
                    <td valign="top" colspan="1" rowspan="1">14 (45.2)</td>
                    <td valign="top" colspan="1" rowspan="1">5 (45.5)</td>
                    <td valign="top" colspan="1" rowspan="1">50 (26.0)</td>
                    <td valign="top" colspan="1" rowspan="1">19 (29.7)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Cardiac disorders</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">2 (3.1)</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">1 (3.2)</td>
                    <td valign="top" colspan="1" rowspan="1">1 (9.1)</td>
                    <td valign="top" colspan="1" rowspan="1">3 (1.6)</td>
                    <td valign="top" colspan="1" rowspan="1">1 (1.6)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Type 2 diabetes</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">3 (4.6)</td>
                    <td valign="top" colspan="1" rowspan="1">1 (4.8)</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">3 (1.6)</td>
                    <td valign="top" colspan="1" rowspan="1">1 (1.6)</td>
                  </tr>
                  <tr>
                    <td valign="top" colspan="1" rowspan="1">Type 1 diabetes</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">1 (9.1)</td>
                    <td valign="top" colspan="1" rowspan="1">0</td>
                    <td valign="top" colspan="1" rowspan="1">1 (1.6)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="spara008">
                  <p>BMI, body mass index.</p>
                </fn>
                <fn id="spara009">
                  <p>Table parameters presented were predefined. Values are mean (standard deviation) unless otherwise stated.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </p>
        </sec>
        <sec id="sec0019">
          <title>Immunogenicity endpoints</title>
          <sec id="sec0020">
            <title>Coprimary endpoint: antibody responses to AZD1222 spike antigen</title>
            <p id="para0031">Seroresponses to the SARS-CoV-2 spike antigen in the FVS on Day 57 were exhibited by 100% (<italic toggle="yes">n</italic>=174) of participants who received AZD1222 and 0% (<italic toggle="yes">n</italic>=60) of participants who received placebo (<italic toggle="yes">P</italic>&lt;0.001 for AZD1222 vs placebo for both cohorts).</p>
          </sec>
          <sec id="sec0021">
            <title>Secondary immunogenicity endpoints</title>
            <p id="para0032">In participants who received AZD1222, antibody titres for SARS-CoV-2 spike antigen increased substantially after the first dose and increased further after the second dose across all age cohorts/subcohorts in the FVS. Titres peaked on Day 43 and remained above pre-dose Day 29 levels up to Day 57 (<xref rid="fig0002" ref-type="fig">Figure 2</xref>
).<fig id="fig0002" position="float" orientation="portrait">
                <label>Figure 2</label>
                <caption>
                  <p>Box plots and individual plots of anti-spike antibody titres over time after two doses of AZD1222 or placebo in Japanese participants (fully vaccinated analysis set), determined by Meso Scale Discovery serological assay. The bottom and top edges of the box indicate the first and third quartiles [the difference is the interquartile range (IQR)], the line inside the box is the median, and the diamond mark inside the box is the geometric mean. The whiskers that extend from the box indicate the minimum and maximum within the range of 1.5 × IQR from the box. Box plots are created using log-transformed values. Titre values measured as below the lower limit of quantification (LLoQ) (33) are imputed to a value that is half of the LLoQ. Titre values measured as above the upper limit of quantification (ULoQ) (2,000,000) are imputed at the ULoQ value. AU/mL, arbitrary units per mL; S, SARS-CoV-2 spike antigen.</p>
                </caption>
                <alt-text id="alt0003">Figure 2</alt-text>
                <graphic position="float" orientation="portrait" ns0:href="gr2_lrg.jpg" />
              </fig>
            </p>
            <p id="para0033">Results for SARS-CoV-2 RBD antigen were similar to those for the spike antigen (<xref rid="fig0003" ref-type="fig">Figure 3</xref>
). A seroresponse to the SARS-CoV-2 RBD antigen was observed in 100% (<italic toggle="yes">n</italic>=174) of participants who received AZD1222 and 0% (<italic toggle="yes">n</italic>=60) of participants who received placebo in the FVS on Day 57 (<italic toggle="yes">P</italic>&lt;0.001 for AZD1222 vs placebo for both cohorts). nAb responses against SARS-CoV-2 on Day 57 were observed in 67.5% (54/83), 60.3% (35/61) and 50.0% (14/28) of participants receiving AZD1222 in the FVS among the 18–55, 56–69 and ≥70 years age cohorts, respectively. In contrast, no nAb response was observed in any participant receiving placebo. The difference in nAb responses between AZD1222 and placebo was statistically significant in each age cohort (<italic toggle="yes">P</italic>&lt;0.001). Titres for nAb increased in a similar manner to the anti-spike and anti-RBD antibodies, remaining above pre-dose Day 29 levels up to Day 57 (<xref rid="fig0004" ref-type="fig">Figure 4</xref>
). For participants aged 18–55, 56–69 and ≥70 years, peak nAb GMTs on Day 57 were 107.3 (95% CI 84.2–136.7), 101.5 (95% CI 74.3–138.5) and 70.2 (95% CI 45.6–108.1), respectively. In the placebo groups, there was no change from baseline in antibody titres for the SARS-CoV-2 spike and RBD antigens, and nAb for any age cohort.<fig id="fig0003" position="float" orientation="portrait">
                <label>Figure 3</label>
                <caption>
                  <p>Box plots and individual plots of anti-receptor-binding domain (RBD) antibody titres over time after two doses of AZD1222 or placebo in Japanese participants (fully vaccinated analysis set), determined by Meso Scale Discovery serological assay. The bottom and top edges of the box indicate the first and third quartiles [the difference is the interquartile range (IQR)], the line inside the box is the median, and the diamond mark inside the box is the geometric mean. The whiskers that extend from the box indicate the minimum and maximum within the range of 1.5 × IQR from the box. Box plots are created using log-transformed values. Titre values measured as below the lower limit of quantification (LLoQ) (204) are imputed to a value that is half of the LLoQ. Titre values measured as above the upper limit of quantification (ULoQ) (2,000,000) are imputed at the ULoQ value. AU/mL, arbitrary units per mL.</p>
                </caption>
                <alt-text id="alt0004">Figure 3</alt-text>
                <graphic position="float" orientation="portrait" ns0:href="gr3_lrg.jpg" />
              </fig>
              <fig id="fig0004" position="float" orientation="portrait">
                <label>Figure 4</label>
                <caption>
                  <p>Box plots and individual plots of neutralizing antibody (nAb) titres over time after two doses of AZD1222 or placebo in Japanese participants (fully vaccinated analysis set), determined by pseudo-virus neutralization assay. The bottom and top edges of the box indicate the first and third quartiles [the difference is the interquartile range (IQR)], the line inside the box is the median, and the diamond mark inside the box is the geometric mean. The whiskers that extend from the box indicate the minimum and maximum within the range of 1.5 × IQR from the box. Box plots are created using log-transformed values. Titre values measured as below the lower limit of quantification (LLoQ) (40) are imputed to a value that is half of the LLoQ. Titre values measured as above the upper limit of quantification (ULoQ) (787,339) are imputed at the ULoQ value.</p>
                </caption>
                <alt-text id="alt0005">Figure 4</alt-text>
                <graphic position="float" orientation="portrait" ns0:href="gr4_lrg.jpg" />
              </fig>
            </p>
          </sec>
        </sec>
        <sec id="sec0022">
          <title>Coprimary endpoint: safety and reactogenicity</title>
          <sec id="sec0023">
            <title>Solicited AEs</title>
            <p id="para0035">Incidences of solicited local and systemic AEs in the first 6 days are reported in <xref rid="fig0005" ref-type="fig">Figure 5</xref>, <xref rid="fig0006" ref-type="fig">Figure 6</xref>
, respectively. Solicited AEs (within 6 days of any dose) were reported by 85.4% (82/96) and 37.5% (12/32) of participants in the AZD1222 and placebo groups in the 18–55-year-old cohort, 72.3% (47/65) and 19.0% (4/21) in the 56–69-year-old subcohort, and 51.6% (16/31) and 27.3% (3/11) in the ≥70-year-old subcohort, respectively. Across all ages, the most frequently reported solicited AEs within 6 days of any dose of AZD1222 were pain and tenderness at the injection site (local), and malaise, muscle pain, fatigue and headache (systemic). The majority were of mild or moderate severity. Severe solicited AEs occurred in 9.4% (9/96) of participants aged 18–55 years receiving AZD1222, and were not observed in the other age groups. No potentially life-threatening solicited AEs were reported. Solicited local and systemic AEs were most frequently reported in the first 2–4 days following any injection (<xref rid="fig0005" ref-type="fig">Figures 5</xref> and <xref rid="fig0006" ref-type="fig">6</xref>). Solicited AEs were more frequently reported after the first dose than the second (Table S1, see online supplementary material). In participants who received AZD1222, solicited AEs were milder and reported less frequently in those aged ≥70 years compared with those aged 18–55 years and 56–69 years.<fig id="fig0005" position="float" orientation="portrait">
                <label>Figure 5</label>
                <caption>
                  <p>Solicited local adverse events in the first 7 days after any dose of AZD1222 or placebo for participants aged (A) 18–55 years, (B) 56–69 years and (C) ≥70 years (total vaccinated analysis set). Day 1 is the day of vaccination. Participants with more than one event within one interval and category are counted once for maximum severity.</p>
                </caption>
                <alt-text id="alt0006">Figure 5</alt-text>
                <graphic position="float" orientation="portrait" ns0:href="gr5_lrg.jpg" />
              </fig>
              <fig id="fig0006" position="float" orientation="portrait">
                <label>Figure 6</label>
                <caption>
                  <p>Solicited systemic adverse events in the first 7 days after any dose of AZD1222 or placebo for participants aged (A) 18–55 years, (B) 56–69 years and (C) ≥70 years (total vaccinated analysis set). Day 1 is the day of injection. Participants with more than one event within one interval and category are counted once for maximum severity.</p>
                </caption>
                <alt-text id="alt0007">Figure 6</alt-text>
                <graphic position="float" orientation="portrait" ns0:href="gr6_lrg.jpg" />
              </fig>
            </p>
          </sec>
          <sec id="sec0024">
            <title>Unsolicited AEs</title>
            <p id="para0036">Unsolicited AEs (28 days following each dose) for AZD1222 and placebo, respectively, were reported by 28.1% (27/96) and 9.4% (3/32) of participants aged 18–55 years, 21.5 % (14/65) and 28.6% (6/21) in those aged 56–69 years, and 22.6% (7/31) and 27.3% (3/11) in those aged ≥70 years. The majority were of mild or moderate severity. Severe unsolicited AEs occurred in 4.2% (4/96) of participants aged 18–55 years receiving AZD1222, and 3.1% (2/65) and 9.5% (2/21) of participants aged 56–69 years receiving AZD1222 or placebo, respectively. The most common unsolicited AEs were consistent with AEs commonly observed following vaccination, including pain and tenderness at the injection site, fatigue and elevated body temperature (Table S2, see online supplementary material). There were no notable imbalances between AZD1222 and placebo for AEs that were not commonly associated with vaccination. In participants who received AZD1222, unsolicited AEs were milder and reported less frequently in those aged ≥56 years compared with those aged 18–55 years.</p>
          </sec>
          <sec id="sec0025">
            <title>Deaths, SAEs and AESIs</title>
            <p id="para0037">No deaths, SAEs or AESIs were reported among participants receiving AZD1222. Among participants receiving placebo, one SAE of cervical intra-epithelial neoplasia (grade 3) occurred in a 69-year-old female after the first dose. This SAE was considered to be unrelated to placebo and the participant received her second dose as planned.</p>
          </sec>
        </sec>
        <sec id="sec0026">
          <title>Clinical laboratory parameters</title>
          <p id="para0038">No clinically significant differences in haematologic and clinical chemistry parameters were observed in the AZD1222 and placebo groups over time. Isolated increases from baseline in FDA toxicity grades were observed for haematology/chemistry parameters in a minority of participants, but this was not considered clinically significant. A temporary decrease in neutrophils in one male participant was reported in the AZD1222 group as an unsolicited AE (grade 3), and recovered to the normal range within 3 weeks after each vaccination. There was no clinically relevant change in average platelet count in the AZD1222 group compared with the placebo group (Tables S3 and S4, see online supplementary material).</p>
        </sec>
      </sec>
      <sec id="sec0027">
        <title>Discussion</title>
        <p id="para0039">The coprimary objectives of this randomized, placebo-controlled trial were to assess immunogenicity and safety of AZD1222 in a Japanese population.</p>
        <p id="para0040">All measures of immunogenicity indicated a strong humoral response to AZD1222 on Day 57, irrespective of participant age. All participants who received both doses of AZD1222 had seroresponses against the SARS-CoV-2 spike and RBD antigens on Day 57. nAb response rates were 62.0% among participants who received two doses of AZD1222, ranging from 50.0% in those aged ≥70 years to 67.5% in those aged 18–55 years. Titre values of anti-spike antibodies, anti-RBD antibodies and nAb increased substantially after the first dose of AZD1222 (Day 29), and increased further after the second dose (Day 57).</p>
        <p id="para0041">Seroresponse rates against SARS-CoV-2 spike and RBD antigens were almost identical to those reported in a pooled analysis of trials conducted in the UK, Brazil and South Africa, in which the majority of participants were white (seroresponse rates ∼100%) (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>), although the respective titre values in this study were less than reported previously (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>). nAb response rates and titres were also numerically lower than observed in the pooled analysis, although this is likely to be due to differences in intervals between first and second doses (4 weeks ±2 days in this study compared with 3–26 weeks for the pooled analysis) (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>). However, nAb titres observed in this study (overall GMT 97.96) were comparable with those in clinical trials conducted in the UK (GMT 97.43) and Brazil (GMT 110.96), which employed similar dosing intervals (4–8 weeks) to this study (<xref rid="bib0021" ref-type="bibr">Pharmaceuticals and Medical Devices, 2021</xref>). Furthermore, the GMTs observed for anti-spike antibodies, anti-RBD antibodies and nAb after the first dose of AZD1222 were comparable between Japanese and non-Japanese participants (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>).</p>
        <p id="para0042">In this study, there was a decreasing trend in anti-spike antibodies, anti-RBD antibodies and nAb titres with increasing age, although large variability was observed among individual titres with wide, overlapping CIs between age groups. These data align with the reduced humoral responses observed in older adults in the previous pooled analysis (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>). However, given the robust vaccine efficacy of AZD1222 observed previously in adults aged &gt;65 years (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>), these numerically reduced responses may not be clinically meaningful.</p>
        <p id="para0043">Correlates of protection have not yet been established for SARS-CoV-2 in humans, although nAb titres have been correlated with protection in non-human primates (<xref rid="bib0006" ref-type="bibr">Deng et al., 2020</xref>; <xref rid="bib0027" ref-type="bibr">van Doremalen et al., 2020a</xref>, <xref rid="bib0028" ref-type="bibr">van Doremalen et al., 2020b</xref>; <xref rid="bib0036" ref-type="bibr">Yu et al., 2020</xref>; <xref rid="bib0017" ref-type="bibr">McMahan et al., 2021</xref>). In addition, several studies have suggested that the presence of nAb is associated with protection in humans (<xref rid="bib0001" ref-type="bibr">Addetia et al., 2020</xref>; <xref rid="bib0025" ref-type="bibr">Robbiani et al., 2020</xref>; <xref rid="bib0031" ref-type="bibr">Wang et al., 2020</xref>; <xref rid="bib0013" ref-type="bibr">Hall et al., 2021</xref>; <xref rid="bib0014" ref-type="bibr">Hansen et al., 2021</xref>; <xref rid="bib0015" ref-type="bibr">Harvey et al., 2021</xref>; <xref rid="bib0016" ref-type="bibr">Krammer, 2021</xref>; <xref rid="bib0022" ref-type="bibr">Pilz et al., 2021</xref>). In this study, AZD1222 elicited a strong humoral immune response against SARS-CoV-2 in Japanese adults, irrespective of age. This suggests that AZD1222 may provide effective protection against COVID-19 in this population, extrapolated from immunogenicity and efficacy results observed in the previous pooled analysis (<xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>, <xref rid="bib0030" ref-type="bibr">Voysey et al., 2021b</xref>).</p>
        <p id="para0044">AZD1222 was well tolerated in Japanese adults across all age groups, and the safety profile was similar to that observed in previous clinical trials (<xref rid="bib0012" ref-type="bibr">Folegatti et al., 2020</xref>; <xref rid="bib0024" ref-type="bibr">Ramasamy et al., 2021</xref>). The most frequently occurring AEs were consistent with previous studies of AZD1222, and included pain and tenderness at the injection site, malaise, fatigue, muscle pain and headache. Up to Day 57, no vaccine-related SAEs were reported, and no deaths have been reported in the trial to date.</p>
        <p id="para0045">Extremely rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been observed following vaccination with AZD1222 during postauthorization use. While no cases of TTS were observed in this study, given the rarity of TTS, no events would be expected in a clinical trial setting such as this; in other studies of the large AZD1222 clinical trial programme, no cases were observed among approximately 30,000 participants who received AZD1222 (<xref rid="bib0011" ref-type="bibr">Falsey, 2021</xref>; <xref rid="bib0029" ref-type="bibr">Voysey et al., 2021a</xref>). Independent safety reviews by regulatory authorities have concluded that the overall protective benefits of AZD1222 against COVID-19, including severe disease, hospitalization and death, outweigh the risks of TTS (<xref rid="bib0008" ref-type="bibr">European Medicines Agency, 2021a</xref>; <xref rid="bib0018" ref-type="bibr">Medicines and Healthcare Products Regulatory Agency, 2021a</xref>; <xref rid="bib0032" ref-type="bibr">World Health Organization 2021</xref>). In individuals with a history of heparin-induced thrombocytopenia and thrombosis or cerebral venous sinus thrombosis, AZD1222 should only be considered where the benefits outweigh any potential risks (<xref rid="bib0009" ref-type="bibr">European Medicines Agency, 2021b</xref>; <xref rid="bib0019" ref-type="bibr">Medicines and Healthcare Products Regulatory Agency, 2021b</xref>). Careful monitoring of safety, including anaphylactic reactions, immune-mediated neurologic disorders and TTS, continues in postmarketing surveillance.</p>
        <p id="para0046">Limitations of this study include the small sample size and short duration of follow-up reported (∼8 weeks after first dose). Pregnant women, individuals with immunodeficiency, and those with severe or uncontrolled underlying disease were excluded from this study, and the results may not be generalized to these populations. Long-term follow-up of this study (Day 365 after first dose), other ongoing clinical studies and emerging real-world evidence will provide further data to characterize the safety, immunogenicity and efficacy of AZD1222. Although correlates of protection against SARS-CoV-2 remain undefined, it is thought that both humoral and cellular immune responses play a protective role (<xref rid="bib0010" ref-type="bibr">Ewer et al., 2021</xref>). Cellular immunity was not investigated in this study, which focused on the humoral immune response. However, data from a previous phase 1/2 trial in UK adults (18–55 years) demonstrated that AZD1222 induced a T-helper-1-biased CD4+ effector response and cytotoxic CD8+ T-cell response (<xref rid="bib0010" ref-type="bibr">Ewer et al., 2021</xref>). Finally, this study was not designed to evaluate the efficacy of AZD1222, and it cannot be concluded definitively that the immune responses observed correlate with protection.</p>
      </sec>
      <sec id="sec0028">
        <title>Conclusions</title>
        <p id="para0047">AZD1222 elicited a strong humoral immune response against SARS-CoV-2 regardless of age, and was well tolerated with an acceptable safety profile in Japanese adult participants, including the elderly and those with controlled underlying diseases. Results were comparable with data from clinical trials conducted in the UK and Brazil that employed a similar dosing interval to this study, suggesting that AZD1222 can confer effective protection against COVID-19 in the Japanese population.</p>
      </sec>
    </body>
  </article>
</pmc-articleset>